Comparison · NCT00221338-sae
Gabapentin vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Gabapentin vs Placebo: serious adverse events. Trial comparisons, record NCT00221338-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00221338-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0886 | 0.0631 | 0.123 | wilson | |
| Risk in group 2 | 0.127 | 0.0958 | 0.166 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0382 | -0.0849 | 0.00806 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.699 | 0.452 | 1.08 | log | |
| Odds ratio, group 1 over group 2 | 0.669 | 0.412 | 1.09 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Gabapentin than on Placebo | 26.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Gabapentin | Double blind, placebo controlled~Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days | 31 | 350 | EG000 |
| Group 2 | Placebo | Double blind~Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days | 44 | 347 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data were collected over the time period of 1 year.
Source ClinicalTrials.gov
Trial
- Title
- Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain
- NCT number
- NCT00221338
- Phases
- PHASE3
- Conditions
- Postoperative Delirium, Postoperative Pain, Opioid Use, Hospital Length of Stay
- Interventions
- Gabapentin
- Lead sponsor
- University of California, San Francisco
- Results first posted
- 2020-09-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00221338?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00221338-sae